The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population

Elaine Toy, Sripriya Balasubramanian, Carlo Selmi, Chin-Shang Li, Christopher L Bowlus, Elaine Toy, Sripriya Balasubramanian, Carlo Selmi, Chin-Shang Li, Christopher L Bowlus

Abstract

Background: Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic liver disease often associated with inflammatory bowel diseases (IBD). Current epidemiological data are limited to studies of predominantly Caucasian populations. Our aim was to define the epidemiology of PSC in a large, ethnically diverse US population.

Methods: The Northern California Kaiser Permanente (KP) database includes records from over 3 million people and was searched for cases of PSC between January 2000 and October 2006. All identified charts were reviewed for diagnosis confirmation, IBD co-morbidity, and major natural history endpoints.

Results: We identified 169 (101 males) cases fulfilling PSC diagnostic criteria with a mean age at diagnosis of 44 years (range 11-81). The age-adjusted point prevalence was 4.15 per 100,000 on December 31, 2005. The age-adjusted incidence per 100,000 person-years was not significantly greater in men 0.45 (95% CI 0.33-0.61) than women 0.37 (95% CI 0.26-0.51). IBD was present in 109/169 (64.5%) cases and was significantly more frequent in men than women with PSC (73.3% and 51.5%, respectively, p = 0.005). The cumulative average yearly mortality rate was 1.9%. Age and serum sodium, creatinine and bilirubin at diagnosis and albumin at last entry were identified as significant factors associated with death, liver transplant or cholangiocarcinoma.

Conclusions: The incidence and prevalence of PSC observed in a representative Northern California population are lower compared to previous studies in Caucasian populations and this might reflect differences in the incidence of PSC among various ethnic groups.

Figures

Figure 1
Figure 1
Adjusted Incidence Rates of Primary Sclerosing Cholangitis in Northern California by Age and Gender, 2000-2006.

References

    1. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev. 2005;4(3):137–143. doi: 10.1016/j.autrev.2004.09.003.
    1. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–267. doi: 10.1016/j.jhep.2009.04.009.
    1. Faubion WA Jr, Loftus EV, Sandborn WJ, Freese DK, Perrault J. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr. 2001;33(3):296–300. doi: 10.1097/00005176-200109000-00013.
    1. Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54(1):91–96. doi: 10.1136/gut.2004.046615.
    1. Loftus EV Jr, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology. 1996;110(5):1496–1502. doi: 10.1053/gast.1996.v110.pm8613055.
    1. Mitchell SA, Thyssen M, Orchard TR, Jewell DP, Fleming KA, Chapman RW. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut. 2002;51(4):567–573. doi: 10.1136/gut.51.4.567.
    1. van Erpecum KJ, Smits SJ, van de Meeberg PC, Linn FH, Wolfhagen FH, vanBerge-Henegouwen GP, Algra A. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology. 1996;110(5):1503–1506. doi: 10.1053/gast.1996.v110.pm8613056.
    1. Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, Ciusani E, Chapman R, Ercilla G, Fausa O. et al.HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens. 1999;53(5):459–469. doi: 10.1034/j.1399-0039.1999.530502.x.
    1. Karlsen TH, Boberg KM, Vatn M, Bergquist A, Hampe J, Schrumpf E, Thorsby E, Schreiber S, Lie BA. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun. 2007;8(3):275–278. doi: 10.1038/sj.gene.6364377.
    1. Bittencourt PL, Palacios SA, Cancado EL, Carrilho FJ, Porta G, Kalil J, Goldberg AC. Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism. Gut. 2002;51(4):609–610. doi: 10.1136/gut.51.4.609.
    1. Neri TM, Cavestro GM, Seghini P, Zanelli PF, Zanetti A, Savi M, Podda M, Zuin M, Colombo M, Floreani A. et al.Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. Dig Liver Dis. 2003;35(8):571–576. doi: 10.1016/S1590-8658(03)00274-3.
    1. Bowlus CL, Li CS, Karlsen TH, Lie BA, Selmi C. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: Unique clinical and HLA associations. Liver Transplantation. 2010.
    1. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV Jr, Yawn BP, Dickson ER, Melton LJ. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125(5):1364–1369. doi: 10.1016/j.gastro.2003.07.011.
    1. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33(1):99–103. doi: 10.1080/00365529850166284.
    1. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102(5):1042–1049. doi: 10.1111/j.1572-0241.2007.01103.x.
    1. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology. 2004;126(7):1929–1930. doi: 10.1053/j.gastro.2004.04.052.
    1. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48(6):939–944. doi: 10.1016/j.jhep.2008.02.017.
    1. Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52(2):571–577. doi: 10.1002/hep.23678.
    1. Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol. 2002;17(8):908–913. doi: 10.1046/j.1440-1746.2002.02835.x.
    1. Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol. 1996;8(7):685–691.
    1. Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol. 1994;21(5):787–791. doi: 10.1016/S0168-8278(94)80240-8.
    1. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97(9):2402–2407. doi: 10.1111/j.1572-0241.2002.06019.x.
    1. Kochhar R, Goenka MK, Das K, Nagi B, Bhasin DK, Chawla YK, Vaiphei K, Singh K, Dilawari JB. Primary sclerosing cholangitis: an experience from India. J Gastroenterol Hepatol. 1996;11(5):429–433. doi: 10.1111/j.1440-1746.1996.tb00286.x.
    1. Takikawa H, Takamori Y, Tanaka A, Kurihara H, Nakanuma Y. Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res. 2004;29(3):153–159. doi: 10.1016/j.hepres.2004.03.006.
    1. Kamisawa T, Egawa N, Tsuruta K, Okamoto A, Funata N. Primary sclerosing cholangitis may be overestimated in Japan. J Gastroenterol. 2005;40(3):318–319. doi: 10.1007/s00535-004-1543-2.
    1. Kelly P, Patchett S, McCloskey D, Alstead E, Farthing M, Fairclough P. Sclerosing cholangitis, race and sex. Gut. 1997;41(5):688–689. doi: 10.1136/gut.41.5.688.
    1. Simsek H, Schuman BM. Inflammatory bowel disease in 64 black patients: analysis of course, complications, and surgery. J Clin Gastroenterol. 1989;11(3):294–298. doi: 10.1097/00004836-198906000-00010.
    1. Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM. et al.Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101(5):1012–1023. doi: 10.1111/j.1572-0241.2006.00504.x.
    1. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82(5):703–710. doi: 10.2105/AJPH.82.5.703.
    1. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Am J Gastroenterol. 2007;102(7):1429–1435. doi: 10.1111/j.1572-0241.2007.01215.x.
    1. Dobson AJ, Kuulasmaa K, Eberle E, Scherer J. Confidence intervals for weighted sums of Poisson parameters. Stat Med. 1991;10(3):457–462. doi: 10.1002/sim.4780100317.
    1. Karlsen TH, Hampe J, Wiencke K, Schrumpf E, Thorsby E, Lie BA, Broome U, Schreiber S, Boberg KM. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol. 2007;102(1):115–121. doi: 10.1111/j.1572-0241.2006.00928.x.
    1. Rabinovitz M, Gavaler JS, Schade RR, Dindzans VJ, Chien MC, Van Thiel DH. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology. 1990;11(1):7–11. doi: 10.1002/hep.1840110103.
    1. Olsson R, Danielsson A, Jarnerot G, Lindstrom E, Loof L, Rolny P, Ryden BO, Tysk C, Wallerstedt S. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100(5 Pt 1):1319–1323.
    1. Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 1997;40(4):451–456. doi: 10.1007/BF02258391.
    1. Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol. 2005;20(3):366–370. doi: 10.1111/j.1440-1746.2005.03727.x.
    1. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008;103(8):1998–2006. doi: 10.1111/j.1572-0241.2008.01960.x.
    1. Hiatt RA, Kaufman L. Epidemiology of inflammatory bowel disease in a defined northern California population. West J Med. 1988;149(5):541–546.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe